Belgium - Map
Phone: 32 2 559 99 99
Fax: 32 2 559 99 00
UCB S.A., a biopharmaceutical company, discovers and develops therapies primarily for central nervous system (CNS) disorders and immunology diseases worldwide. Its CNS products include Vimpat and Keppra for epilepsy, and Neupro for Parkinsons disease and restless legs syndrome; Nootropil for regulating cerebral functions; and Metadate CD for attention deficit hyperactivity disorder. The company is developing Vimpat, which is under Phase III clinical trials for epilepsy-monotherapy; and brivaracetam for epilepsy-adjunctive therapy, as well as developing Vimpat that has completed Phase II clinical trials for epilepsy-paediatric adjunctive therapy, and epilepsy adjunctive therapy. It is also developing UCB0942, which has completed Phase I clinical trials for refractory epilepsy. The company provides immunology products, such as Cimzia for Crohn's disease and rheumatoid arthritis; Xyzal and Zyrtec for allergies; Tussionex for respiratory disease; and Lortab for pain relief. It is also developing CDP7657 that has completed Phase I clinical trials for systemic lupus erythematosus; and UCB4940, which is under Phase I clinical trial for immunological diseases. The company has a strategic collaboration with Five Prime Therapeutics, Inc. for the discovery of biologics targets and therapeutics in the areas of fibrosis-related inflammatory diseases and CNS disorders; and a strategic partnership with Sanofi for the discovery and development of anti-inflammatory small molecules. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.
|Dr. Frederic Roch Doliveux DVM,
Chief Exec. Officer and Exec. Director
|Mr. Detlef Thielgen ,
Chief Financial Officer and Exec. VP
| Caroline Vancoillie ,
Chief Accounting Officer
| Raf Remijsen ,
Director of Treasury & Corp. Fin.
| Antje Witte ,
VP of Investor Relations
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in EUR.|